Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
RIGImmune Inc. logo — Targeted non-LNP Delivery of RNA Therapeutics

RIGImmune Inc.

Targeted non-LNP Delivery of RNA Therapeutics

Founded 2020 United States Farmington, United States 12 employees Seed Biopharma, Biotechnology +1

General Information

Company Name RIGImmune Inc.
Founded Year 2020
Location United States Farmington, United States
Employees 12
Industries Biopharma, Biotechnology, Pharmaceutical
Funding Stage Seed
Business Model B2B, B2D
Revenue Model Licensing, Product Sales, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with RIGImmune Inc.. To contact RIGImmune Inc., visit rigimmune.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does RIGImmune Inc. compare?

A PDF of RIGImmune Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting RIGImmune Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About RIGImmune Inc.

RIGImmune Inc. is a promising player in the biopharmaceutical industry, with a sharp focus on pioneering RNA therapeutics to tackle serious respiratory diseases. Founded in 2020, this innovative company thrives on the cutting-edge discoveries of co-founders Drs. Akiko Iwasaki and Anna Pyle from Yale University.

With its slogan, "Targeted non-LNP Delivery of RNA Therapeutics," RIGImmune has taken a distinctive approach by developing stem-loop RNA therapeutics (SLRs) and leveraging a proprietary delivery platform called NEED™. In collaboration with SubIntro, and supported by seasoned developers like Drs. Garth Rapeport, Kazuhiro Ito, and Jag Shur, the company aims to enhance the innate immune response against viral respiratory diseases and address conditions like cystic fibrosis.

Headquartered in the United States and active within the biopharma, biotechnology, and pharmaceutical sectors, RIGImmune is yet to make its mark with a significant investment round. This growing entity presents a compelling opportunity for investors interested in transformative medical innovations.

Business keywords: RNA therapeutics, respiratory diseases, SLR technology, nano-emulsion delivery, innate immune response, cystic fibrosis treatment, virus diseases, antitumor immune response, biopharmaceutical research, novel oligonucleotides, targeted drug delivery, non-LNP delivery, proprietary technology, Yale University collaboration, immune-modulating therapies

Services & Products

Development of RNA therapeutics
Delivery Platform for RNA
Targeted Therapeutic Solutions for Respiratory Disorders

Target Customers

Patients with Respiratory Diseases Healthcare Providers Biopharmaceutical Partners Scientific Researchers

No funding data available for RIGImmune Inc. yet.

RIGImmune Inc. Alternatives & Competitors

View All Alternatives
RIGImmune Inc. vs
AusperBio
AusperBio United States

Transforming Patient Lives For a Better Tomorrow

Series B
8 employees
Biopharma, Biotechnology
RIGImmune Inc. vs
MACROPHAGE PHARMA LIMITED
MACROPHAGE PHARMA LIMITED

Empowering the immune system to combat cancer with precision-targeted therapies

Series A
Biotechnology, Pharmaceutical
RIGImmune Inc. vs
Arrakis Therapeutics
Arrakis Therapeutics United States

Arrakis is on a path to bring powerful new RNA-targeted small molecule (rSM) therapies to millions o...

52 employees
Biopharma, Biotechnology
Also compare with: RIGImmune Inc. vs Vial Vial View all alternatives

FAQ About RIGImmune Inc.

Targeted non-LNP Delivery of RNA Therapeutics
RIGImmune Inc. was founded in 2020.
RIGImmune Inc. is headquartered in Farmington, United States.
RIGImmune Inc. operates in Biopharma, Biotechnology and Pharmaceutical. Its work centres on RNA therapeutics, respiratory diseases, SLR technology and nano-emulsion delivery. Its customers include Patients with Respiratory Diseases, Healthcare Providers and Biopharmaceutical Partners.
RIGImmune Inc. has a B2B and B2D business model. Its revenue comes from Licensing, Product Sales and Service Fee.
RIGImmune Inc. has approximately 12 employees.
RIGImmune Inc. offers: Development of RNA therapeutics, Delivery Platform for RNA, Targeted Therapeutic Solutions for Respiratory Disorders.
Top alternatives and competitors to RIGImmune Inc. include AusperBio, MACROPHAGE PHARMA LIMITED, Arrakis Therapeutics, Vial, ReCode Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
RIGImmune Inc. and AusperBio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for RIGImmune Inc., https://bouncewatch.com/company/rigimmune-inc, updated 11 March 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes